


Fact Sheet

May 2018


Targeted Treatment and Diagnosis of Inflammation: Cancer, Sepsis, Arthritis, Retinopathy & Atherosclerosis

SignaBlok's first-in-class therapeutics and diagnostics open new avenues for targeted treatment and diagnosis of cancer, arthritis, sepsis, retinopathy, and atherosclerosis


CANCER




ARTHRITIS




SEPSIS



RETINOPATHY



ATHEROSCLEROSIS



SignaBlok, Inc. is a privately held biotech company based in Massachusetts and focused on the development and commercialization of first-in-class, novel targeted therapies and diagnostics for cancer, arthritis, retinopathy, sepsis, and atherosclerosis using the company's own intellectual property.

SCHOOL Peptide Therapeutics

SignaBlok's model of cell signaling, the Signaling Chain HOmoOLigomerization (SCHOOL) model, explains for the first time the mechanisms of transmembrane signal transduction mediated by immune receptors. This discovery has led to a novel approach to modulation of receptor signaling and enables the rational design of new, receptor-specific inhibitory peptides (SCHOOL peptides) for therapeutic purposes.

The inhibitory SCHOOL peptides mimic the structures found in nature, employ novel, ligand-independent mechanisms of action, possess unique and beneficial properties and can be used alone or in combination with other therapies. These peptides are non-immunogenic, non-toxic, simple and cheap to manufacture.

Integrated Nanosystems for Targeted Delivery

SignaBlok is developing multifunctional nanosystems for targeted delivery of SCHOOL peptides as well as other drugs and/or imaging agents to macrophages with applications in diagnosis and treatment of cancer, arthritis, retinopathy, sepsis, atherosclerosis, and other diseases with unmet clinical needs.

Company Milestones

- 2009**
 - Company founded
 - Business model developed
- 2010**
 - IP developed and filed
- 2012**
 - **Animal proof-of-concept:**
 - sepsis prevention and treatment
 - targeted drug delivery
 - Partnership with the UT Southwestern Medical Center on cancer cachexia
- 2013**
 - **Animal proof-of-concept:**
 - lung cancer treatment
 - early diagnosis of atherosclerosis
 - US patent for novel peptide therapies
- 2014**
 - Partnership with the UMass Medical School on atherosclerosis
- 2015**
 - **Animal proof-of-concept:**
 - rheumatoid arthritis treatment
- 2016**
 - **Animal proof-of-concept:**
 - pancreas cancer treatment
 - retinopathy treatment
 - Partnership with the Augusta University on retinopathy
- 2017**
 - **Animal proof-of-concept:**
 - liver disease treatment
 - Partnership with the UMass Medical School on liver diseases
- 2018**
 - Partnership with the Feinstein Institute for Medical Research on glioblastoma multiforme

Contact Us

Alexander Sigalov, PhD
President, Inventor & Founder

Tel: (203) 505-3807
sigalov@signablok.com